


403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.







Insider Trading - Accipiter Life Sciences Fund Lp - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Accipiter Life Sciences Fund Lp





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-11-09Sale
2016-11-147:32 pm
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
577,546
$7.142
$4,125,072
4,798,951(Indirect)
View


2015-12-31Purchase
2016-01-054:38 pm
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
11,778
$2.89
$34,038
4,798,951(Indirect)
View


2015-12-29Purchase
2015-12-307:22 pm
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
189,591
$2.875
$545,003
4,787,173(Indirect)
View


2015-12-18Purchase(A)
2015-12-2811:19 am
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
34,150
$2.878
$98,281
4,696,248(Indirect)
View


2015-12-21Purchase
2015-12-234:50 pm
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
24,494
$2.877
$70,472
4,691,617(Indirect)
View


2015-12-15Purchase
2015-12-175:22 pm
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
112,715
$2.744
$309,251
4,679,867(Indirect)
View


2015-12-10Purchase
2015-12-145:57 pm
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
147,057
$2.579
$379,259
4,625,794(Indirect)
View


2015-12-07Purchase
2015-12-096:43 pm
Foresight Energy Lp
FELP
Accipiter Capital Management LLCAccipiter Life Sciences Fund LpAccipiter Life Sciences Fund Offshore LtdCandens Capital LLCHoffman Gabe10% Owner
1,308,344
$2.571
$3,364,360
4,555,244(Indirect)
View




 (A) Indicate amendment filing.
 





    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 21 Jul 2017 21:15:51 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  











403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.






	Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Pharmaceutical Board at the 2008













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Pharmaceutical (PPCO) Board at the 2008 Annual Meeting  











Tweet








2/18/2008 6:42:40 AM


    NEW YORK, Feb. 15 /PRNewswire/ -- Accipiter Life Sciences Fund, LP ("Accipiter Life Sciences"), announced today that it has nominated Gabe Hoffman, David Lohman and Eugene I. Davis for election to the Board of Directors of Penwest Pharmaceuticals Co. (the "Company")  at the Company's 2008 Annual Meeting of Shareholders.  The Company has not announced the date of the annual meeting.  Accipiter Life Sciences, which, together with its affiliates, beneficially owns 2,168,213 shares, or approximately 9.3% of the outstanding shares, of common stock of the Company, submitted written notice of the nominations to the Company's Corporate Secretary in a letter dated February 15, 2008.                 CERTAIN INFORMATION CONCERNING PARTICIPANTS    Accipiter Life Sciences Fund, LP ("Accipiter Life Sciences"), together with the other Participants (as defined below), intend to make a preliminary filing with the Securities and Exchange Commission ("SEC") of a proxy statement and accompanying proxy card to be used to solicit votes for the election of a slate of director nominees at the 2008 annual meeting of shareholders of Penwest Pharmaceuticals Co., a Washington corporation (the "Company").    ACCIPITER LIFE SCIENCES ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT WHEN IT IS AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION.  SUCH PROXY STATEMENT WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV.  IN ADDITION, THE PARTICIPANTS IN THE SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE UPON REQUEST.  REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.    The participants in the proxy solicitation are anticipated to be Accipiter Life Sciences Fund (Offshore), Ltd., ("ALS Fund Offshore"), Accipiter Life Sciences Fund II, LP, ("ALS Fund II"), Accipiter Life Sciences Fund II (Offshore), Ltd., ("ALS Fund II Offshore"), Accipiter Life Sciences Fund II (QP), LP, ("ALS Fund II QP") (together with Accipiter Life Sciences, ALS Fund Offshore, ALS Fund II, ALS Fund II Offshore, ALS Fund II QP, the "Accipiter Entities"), Accipiter Capital Management, LLC, ("Accipiter Management"), Candens Capital, LLC,  ("Candens Capital"), Gabe Hoffman, David Lohman and Eugene I. Davis.  As of the date of this filing, Accipiter Life Sciences, ALS Fund II and ALS Fund II QP beneficially owned 555,745, 254,029 and 290,330 shares of Common Stock of the Company, respectively.  As the general partner of each of Accipiter Life Sciences, ALS Fund II and ALS Fund II QP, Candens Capital may be deemed to beneficially own the 1,100,104 shares of Common Stock of the Company collectively owned by Accipiter Life Sciences, ALS Fund II and ALS Fund II QP.    As of the date of this filing, ALS Fund Offshore and ALS Fund II Offshore beneficially owned 557,048 and 511,061 shares of Common Stock of the Company, respectively.  As the investment manager of each of ALS Fund Offshore and ALS Fund II Offshore, Accipiter Management may be deemed to beneficially own the 1,068,109 shares of Common Stock of the Company collectively owned by ALS Fund Offshore and ALS Fund II Offshore.    As of the date of this filing Mr. Hoffman may be deemed to beneficially own 2,168,213 shares of Common Stock collectively owned by the Accipiter Entities.  Mr. Hoffman has sole voting and dispositive power with respect to the 2,168,213 Shares owned by the Accipiter Entities.  Each of Candens Capital, Accipiter Management and Gabe Hoffman disclaims beneficial ownership of the shares of Common Stock of the Company owned by the Accipiter Entities except to the extent of its or his pecuniary interest therein.  Currently, each of Messrs. Lohman and Davis do not beneficially own any shares of Common Stock of the Company.  As members of a "group" for the purposes of Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended, each of Messrs. Lohman and Davis are deemed to beneficially own the 2,168,213 shares of Common Stock owned by the Accipiter Entities.CONTACT:  Gabe Hoffman, Accipiter Capital Management, LLC, +1-212-705-8700 






                Read at
                BioSpace.com







Related News
Penwest Pharmaceutical (PPCO) Pain Drug Fails Main Goal in Trial  TorreyPines Therapeutics, Inc. (TPTX) to Reduce Work Force to Streamline Operations  Endo Pharmaceuticals (ENDP) and Penwest Pharmaceutical (PPCO) Receive Paragraph IV Certification Notice From Actavis for OPANA(R) ER  Jacques Biton Named CEO of Deinove Endo Pharmaceuticals (ENDP) and Penwest Pharmaceutical (PPCO) File Lawsuit Against IMPAX Laboratories, Inc. (IPXL) Relating to OPANA(R) ER  Aastrom Biosciences, Inc. (ASTM) Announces Transition of Duties; CFO Retires  Endo Pharmaceuticals Holdings Inc. (ENDP) and Penwest Pharmaceutical (PPCO) Receive New Paragraph IV Certification Notice From IMPAX Laboratories, Inc. (IPXL) for OPANA(R) ER  BiPar Sciences, Inc. Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
  Penwest Pharmaceutical (PPCO) Completes Patient Enrollment in Phase IIa Clinical Study of Nalbuphine ER  AVI BioPharma, Inc. (AVII) Names Dr. Leslie Hudson as Chief Executive Officer  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Penwest Pharmaceutical



                            •
                            Accipiter Life Sciences




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 































ACCIPITER LIFE SCIENCES FUND LP - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











ACCIPITER LIFE SCIENCES FUND LP
Check out list of companies and businesses related to ACCIPITER LIFE SCIENCES FUND LP. Find out ACCIPITER LIFE SCIENCES FUND LP address and contact details. View other people related to ACCIPITER LIFE SCIENCES FUND LP - coworkers, colleagues, companions, etc.
Address:   

399 PARK AVENUE 38TH FLOOR NEW YORK 10022 NY




Companies related to ACCIPITER LIFE SCIENCES FUND LP
CIKCompany NamePositionCompany Address0000906326RURAL/METRO CORP /DE/9221 EAST VIA DE VENTURA  SCOTTSDALE 852580001107216ORCHID CELLMARK INC4390 US ROUTE ONE  PRINCETON 085400001540729Foresight Energy LP211 NORTH BROADWAY, SUITE 2600  ST. LOUIS 63102




ACCIPITER LIFE SCIENCES FUND LP on the Web
Persons related to ACCIPITER LIFE SCIENCES FUND LP - RURAL/METRO CORP /DE/NamePositionCityACCIPITER CAPITAL MANAGEMENT, LLC10% Owner NEW YORKACCIPITER CAPITAL MANAGEMENT, LLC10% Owner NEW YORKACCIPITER LIFE SCIENCES FUND II L PNEW YORKACCIPITER LIFE SCIENCES FUND II L PNEW YORKAccipiter Life Sciences Fund II Offshore LtdNEW YORKAccipiter Life Sciences Fund II Offshore LtdNEW YORKACCIPITER LIFE SCIENCES FUND II QP L PNEW YORKACCIPITER LIFE SCIENCES FUND II QP L PNEW YORKACCIPITER LIFE SCIENCES FUND OFFSHORE LTDNEW YORKACCIPITER LIFE SCIENCES FUND OFFSHORE LTDNEW YORKBrian O  AllerySr. VP & Chief Admin. Officer SCOTTSDALEGregory A  BarberSCOTTSDALEPONCZAK KRISTINE A  BEIANSCOTTSDALEPONCZAK KRISTINE A  BEIANSr. VP, CFO & Secretary SCOTTSDALEDonna  BerlinskiVP, PAO, Controller SCOTTSDALEJACK E  BRUCKERPresident & CEO SCOTTSDALEJACK E  BRUCKERPresident & CEO SCOTTSDALEJACK E  BRUCKERPresident and CEO SCOTTSDALEJACK E  BRUCKER SCOTTSDALECandens Capital LLCNEW YORKCandens Capital LLCNEW YORKColiseum Capital Management, LLC10% Owner NEW YORKColiseum Capital Management, LLC10% Owner NEW YORKA CONRAD  CONRADDirector SCOTTSDALEEUGENE I  DAVISDirector SCOTTSDALEMICHAEL P  DIMINOPresident and CEO SCOTTSDALEA/S  FalckCOPENHAGEN VA/S  FalckCOPENHAGEN VA/S  FalckPOLITITORVET, COPENHAGEN VDanmark A/S  Falck10% Owner COPENHAGEN VDanmark A/S  FalckCOPENHAGEN VDanmark A/S  Falck10% Owner POLITITORVET, COPENHAGEN VDanmark A/S  Falck10% Owner POLITITORVET, COPENHAGEN VHolding A/S  FalckCOPENHAGEN VHolding A/S  FalckCOPENHAGEN VHolding A/S  FalckPOLITITORVET, COPENHAGEN VHolding A/S  FalckPOLITITORVET, COPENHAGEN VMickeul B.  GibsonExecutive VP and COO SCOTTSDALEGABE  HOFFMANNEW YORKGABE  HOFFMANNEW YORKEARL P  HOLLANDDirector SCOTTSDALELOUIS G  JEKELDirector SCOTTSDALECHARLES R  KAYENEW YORKChristopher E.  KevaneSr. VP & General Counsel SCOTTSDALEKurt  KrumpermanSCOTTSDALEBARRY D  LANDONSr. VP - Nat'l Billings & Coll SCOTTSDALEJOSEPH  LANDYNEW YORKMatthew J  MajorosSCOTTSDALEMOHSIN Y  MEGHJINEW YORKKevin  MooreDirector SCOTTSDALENordic Capital V Alpha LtdJERSEY, CHANNEL ISLANDSNordic Capital V Alpha LtdCHANNEL ISLANDSNordic Capital V Alpha LtdCHANNEL ISLANDSNordic Capital V LtdJERSEY, CHANNEL ISLANDSNordic Capital V LtdCHANNEL ISLANDSNordic Capital V LtdCHANNEL ISLANDSNordic Capital V LtdCHANNEL ISLANDSNordic Capital V LtdCHANNEL ISLANDSJeff D  PerrySr. Vice President and C.I.O. SCOTTSDALEChristopher S  ShackeltonDirector NEW YORKChristopher S  ShackeltonDirector NEW YORKSTADIUM CAPITAL MANAGEMENT LLCBENDTENNENBAUM CAPITAL PARTNERS LLC10% Owner SANTA MONICATENNENBAUM & CO LLCSANTA MONICAMICHAEL E  TENNENBAUMSANTA MONICAMaureen E  ThompsonSCOTTSDALENicole  ViglucciNEW YORKHENRY G  WALKERDirector SCOTTSDALEWARBURG PINCUS & CONEW YORKWARBURG PINCUS LLCNEW YORKWarburg Pincus Partners LLCNEW YORKWarburg Pincus Private Equity X, L.P.NEW YORKWarburg Pincus X, L.P.NEW YORKWarburg Pincus X LLCNEW YORKWARBURG PINCUS X PARTNERS, L.P.NEW YORKROBERT E  WILSONDirector SCOTTSDALELOUIS A  WITZEMANDirector SCOTTSDALEWP Rocket Holdings Inc.10% Owner NEW YORKWP Rocket Holdings LLCNEW YORKPersons related to ACCIPITER LIFE SCIENCES FUND LP - ORCHID CELLMARK INCNamePositionCityACCIPITER CAPITAL MANAGEMENT, LLC10% Owner NEW YORKACCIPITER CAPITAL MANAGEMENT, LLC10% Owner NEW YORKACCIPITER LIFE SCIENCES FUND II L PNEW YORKACCIPITER LIFE SCIENCES FUND II L PNEW YORKAccipiter Life Sciences Fund II Offshore LtdNEW YORKAccipiter Life Sciences Fund II Offshore LtdNEW YORKACCIPITER LIFE SCIENCES FUND II QP L PNEW YORKACCIPITER LIFE SCIENCES FUND II QP L PNEW YORKACCIPITER LIFE SCIENCES FUND OFFSHORE LTDNEW YORKACCIPITER LIFE SCIENCES FUND OFFSHORE LTDNEW YORKBRUCE F  BASARABV.P., N.A. Sales and Marketing PRINCETONBRUCE F  BASARABVP N.A. Sales and Marketing PRINCETONJAMES  BEERYDirector COLUMBIAJAMES  BEERYDirector PRINCETONJAMES  BEERYChairman of the Board PRINCETONJAMES  BEERYDirector PRINCETONTHOMAS A  BOLOGNAPresident and CEO PRINCETONTHOMAS A  BOLOGNAPresident and CEO PRINCETONTHOMAS A  BOLOGNAPresident and CEO PRINCETONTHOMAS A  BOLOGNAPRINCETONJeffrey S.  BoschwitzVP, North America Mkt & Sales PRINCETONJeffrey S.  BoschwitzVP, North America Mkt & Sales PRINCETONJames T. Jr.  BoyleBURLINGTONBRIDGER CAPITAL LLCNEW YORKBRIDGER MANAGEMENT LLC10% Owner NEW YORKGordon  BrownSenior VP-Global Lab Operation PRINCETONGordon  BrownFormer Executive Officer CHURCHVILLECandens Capital LLCNEW YORKCandens Capital LLCNEW YORKCandens Capital LLCNEW YORKJenniffer  Collins PRINCETONBRUCE D  DALZIELDirector PRINCETONEUGENE I  DAVISLIVINGSTONJohn  DeighanPRINCETONJohn  DeighanCorporate Controller - PAO PRINCETONF SAMUEL  EBERTS IIIBURLINGTONJames M.  HartDirector PRINCETONWilliam B  HayesBURLINGTONSIDNEY M  HECHTDirector PRINCETONSIDNEY M  HECHTDirector PRINCETONSIDNEY M  HECHTDirector PRINCETONGABE  HOFFMANNEW YORKGABE  HOFFMANGABE  HOFFMANNEW YORKSAMUEL D  ISALYPAUL JAMES  KELLYChief Executive Officer PAUL JAMES  KELLYChief Executive Officer PRINCETONPAUL JAMES  KELLY WELLESLEYPHILIP B  KORSANTGREENWICHLABORATORY CORP OF AMERICA HOLDINGS10% Owner BURLINGTONLABORATORY CORP OF AMERICA HOLDINGS10% Owner BURLINGTONRAYMOND J  LANDSr. Vice President and CFO PRINCETONStefan  LorenBALTIMOREROBERTO  MIGNONENEW YORKDavid M  MurphyCorporate Controller, PAO, PFO PRINCETONKENNETH D  NOONANDirector KENNETH D  NOONANDirector PRINCETONKENNETH D  NOONANDirector PRINCETONKENNETH D  NOONANDirector PRINCETONPBK HOLDINGS INCGREENWICHGEORGE  POSTEDirector REDWOOD CITYGEORGE  POSTEDirector PRINCETONGEORGE  POSTEDirector PRINCETONGEORGE  POSTEDirector PRINCETONJAMES FRANCIS  SMITHVice President and CFO PRINCETONJAMES FRANCIS  SMITHVice President and CFO PRINCETONMICHAEL E B  SPICERChief Finanical Officer MICHAEL E B  SPICERChief Finanical Officer PRINCETONSWIFTCURRENT OFFSHORE LTDNEW YORKPARTNERS  SWIFTCURRENTNEW YORKWilliam John  ThomasVP & General Counsel PRINCETONWilliam John  ThomasVP & General Counsel PRINCETONROBERT D  TIENDirector PRINCETONder Vaart Sandra D  vanBURLINGTONAndrew Scott  WaltonBURLINGTONGordon J  WassermanDirector PRINCETONNICOLE  WILLIAMSDirector NICOLE  WILLIAMSDirector PRINCETONNICOLE  WILLIAMSDirector PRINCETONNICOLE  WILLIAMSDirector PRINCETONZIFF ASSET MANAGEMENT LP10% Owner GREENWICHPersons related to ACCIPITER LIFE SCIENCES FUND LP - Foresight Energy LPNamePositionCityACCIPITER CAPITAL MANAGEMENT, LLC10% Owner NEW YORKACCIPITER LIFE SCIENCES FUND OFFSHORE LTDNEW YORKMichael John  BeyerPresident & CEO ST. LOUISMichael John  BeyerPresident & CEO ST. LOUISRashda Miriam  ButtarSen VP-Gen Counsel & Corp Sec ST. LOUISRashda Miriam  ButtarSVP - Gen Counsel & Corp Secy ST. LOUISCandens Capital LLCNEW YORKG Nicholas Jr.  CaseyDirector ST. LOUISChristopher  Cline10% Owner PALM BEACH GARDENSChristopher  ClineDirector PALM BEACH GARDENSChristopher  ClineST. LOUISCline Trust Co LLCPALM BEACH GARDENSJohn Franklin  DickinsonDirector PALM BEACH GARDENSForesight Energy GP LLCSAINT LOUISForesight Reserves, LP10% Owner PALM BEACH GARDENSForesight Reserves, LPPALM BEACH GARDENSE Hunter  HarrisonDirector WELLINGTONE Hunter  HarrisonDirector ST. LOUISBennett K  HatfieldDirector ASHLANDDaniel S  HermannDirector ST. LOUISDaniel S  HermannDirector SAINT LOUISGABE  HOFFMANNEW YORKDonald R  Holcomb10% Owner HOUSTONEdward Bartow  JonesST. LOUISOscar Andres  MartinezSenior Vice President  - CFO ST. LOUISOscar Andres  MartinezSVP - CFO ST. LOUISRobert D.  MoorePresident & CEO ST. LOUISRobert Dean  MooreST. CLAIRSVILLEChristopher N  MoravecEVP - CCO LEXINGTONChristopher N  MoravecSenior Vice President ST. LOUISChristopher N  MoravecSVP - CCO ST. LOUISJames T  MurphyST. LOUISMurray Energy CorpST. CLAIRSVILLEEnergy Holdings Co.  MurrayST. CLAIRSVILLERobert Edward  MurrayST. CLAIRSVILLERobert Eugene  MurrayDirector ST. CLAIRSVILLERobert E. Murray TrustST. CLAIRSVILLEBrian D  SullivanDirector BRISTOLPaul H  ViningRICHMOND
Potentially same personNameCityCountryACCIPITER LIFE SCIENCES FUND LPNEW YORKNYACCIPITER LIFE SCIENCES FUND LPACCIPITER LIFE SCIENCES FUND LPNEW YORKNYACCIPITER LIFE SCIENCES FUND LPNEW YORKNY












 








ACCIPITER LIFE SCIENCES FUND, LP New York - Business Profiles





















Business Profile

Document Delivery
API
About





 

 

 Companies
 Officers

 








Home  /  
New York
  /  
ACCIPITER LIFE SCIENCES FUND, LP





Account  


Login


Sign Up






Saved

0




Cart

0













ACCIPITER LIFE SCIENCES FUND, LP


 New York

 NY-2846979
 



 Active



ACCIPITER LIFE SCIENCES FUND, LP was formed on 2002-11-04 in New York. It is currently active.




Save Profile  










FORMATION DETAILS


Registration Number: 2846979
Status: Active
Date of Formation: 2002-11-04
Stock Ownership: &nbsp;,
No Information Available,
&nbsp;
Name History: NOV 04, 2002, Actual, ACCIPITER LIFE SCIENCES FUND, LP





LOCATIONS






A
Address


CANDENS CAPITAL LLC,
153 E 53RD STREET,
NEW YORK, NEW YORK, 10022







RELATED COMPANIES



ACCIPITER LIFE SCIENCES FUND, LP
(Delaware)


ACCIPITER LIFE SCIENCES FUND, LP
(Delaware)


ACCIPITER LIFE SCIENCES FUND, LP
(New York)


ACCIPITER LIFE SCIENCES FUND (QP), LP
(New York)


ACCIPITER LIFE SCIENCES FUND II, LP
(Delaware)





ABOUT THE AREA (ZIP CODE 10022)


Retail trade is a major industry in this area, with 636 businesses (10% of total)
Annual payroll in $1,000: 19,021,964
Paid employees for pay period including March 12: 137,138




DID YOU KNOW?



Where prestige businesses are concerned, New York enjoys both Wall Street and the strongest financial sector business presence in the nation.

















Home
Document Delivery
API
About

© 2017, Business Profiles Inc.
Business Profile





USA
Europe
Asia & Pacific
Americas





Alabama


Alaska


Arizona


Arkansas


California




Colorado


Connecticut


Delaware


District of Columbia


Florida




Georgia


Hawaii


Idaho


Illinois


Indiana




Iowa


Kansas


Kentucky


Louisiana


Maine




Maryland


Massachusetts


Michigan


Minnesota


Mississippi




Missouri


Nevada


New Hampshire


New Jersey


New York




North Carolina


North Dakota


Ohio


Oklahoma


Oregon




Pennsylvania


Puerto Rico


South Carolina


South Dakota


Tennessee




Texas


Utah


Virginia


Washington


Wyoming






Croatia


Denmark


Estonia




Finland


France




Germany


Gibraltar




Ireland


Isle of Man




Luxembourg


Netherlands




Norway


Poland




Slovenia


Spain




Sweden


Switzerland




Turkey


United Kingdom






Australia




Hong Kong




India




New Zealand




Singapore




Thailand












Canada




Colombia




Dominican Republic




Jamaica




Jersey




Mexico




Nova Scotia




Panama




Quebec











  YM BIOSCIENCES SHAREHOLDING IN COMPANY










































FR























×
Member Sign In


Online Member Centre

Cision Communications Cloud

Cision PR Edition

CisionPoint

MediaSource Monitoring/Evaluation

Visible Intelligence

FastFinder

My CNW

CNW Access

Register for my CNW



Close










×
Search




Search



 Go !








 Advanced Search 


 Close 

















 See more news releases in      Biotechnology   Medical Pharmaceuticals  

YM BIOSCIENCES SHAREHOLDING IN COMPANY




























































 


















    MISSISSAUGA, ON, Jan. 18 /CNW/ - YM BioSciences Inc. (AMEX:  YMI, TSX:YM,
AIM:YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today announced that it has
been notified that Accipiter Life Sciences Fund, LP and affiliated funds now
hold 3,497,795 Common Shares in the Company.

    
                                             No. of Total          % issued
                                            Voting Rights     share capital
    Accipiter Life Sciences Fund, LP            1,258,203               2.3%
    Accipiter Life Sciences Fund II, LP           240,657               0.4%
    Accipiter Life Sciences Fund (Offshore)
     Ltd                                        1,246,531               2.2%
    Accipiter Life Sciences Fund II
     (Offshore) Ltd                               476,897               0.9%
    Accipiter Life Sciences Fund II (QP), LP      275,507               0.5%
    

    The holding of 3,497,795 Common Shares represents 6.3% of the current
total issued share capital of the Company, being 58,216,309 Common shares.
    This press release is being issued in order to comply with Rule 26 of the
AIM Rules for Companies.

    About YM BioSciences

    YM BioSciences Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. The Company has
two late-stage products: nimotuzumab, a humanized monoclonal antibody that
targets the epidermal growth factor receptor (EGFR) and is approved in several
countries for treatment of various types of head and neck cancer; and
AeroLEF(TM), a proprietary, inhaled-delivery composition of free and
liposome-encapsulated fentanyl in development for the treatment of moderate to
severe pain, including cancer pain.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(TM) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00004652E




 For further information:  
For further information: Enquiries: Thomas Fechtner, the Trout Group
LLC, Tel. (646) 378-2931, Email: tfechtner@troutgroup.com; James Smith, the
Equicom Group Inc., Tel. (416) 815-0700 x 229, Email: jsmith@equicomgroup.com;
Nominated Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050
6500









  Release contains wide tables.
					  View fullscreen.
			




 Organization Profile







Gilead Sciences, Inc.



Gilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection


Multiple Provinces and Territories Demonstrate Leadership in the Treatment of HIV/AIDS by Providing Access to GENVOYA®


Québec Demonstrates Leadership in the Treatment of HIV/AIDS by Providing Access to GENVOYA®

 More on this organization
 







Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Start today.




CNW Membership
Fill out a CNW membership form or contact us at 1 (877) 269-7890




Learn about CNW services
Request more information about CNW products and services or call us at 1 (877) 269-7890






















































SEC Info - Accipiter Life Sciences Fund LP, et al. - �4� for 9/5/07 re: Orchid Cellmark Inc










SEC Info uses JavaScript!� To view pages properly, enable JavaScript in your browser.


����SEC Info������Home������Search������My Interests������Help������Sign In������Please Sign In




Accipiter Life Sciences Fund LP, et al. � �4��for�9/5/07 re:�Orchid Cellmark IncOn:� Friday, 9/7/07, at 5:14pm ET � � � For:� 9/5/07 � � � As:� 10% Owner and Other � � � Accession #:� 921895-7-2096 � � � File #:� 0-30267
Previous ‘4’:� ‘4’ on 8/30/07 for 8/28/07 � � � Next:� ‘4’ on 11/26/07 for 11/21/07 � � � Latest:� ‘4’ on 2/16/17 for 2/14/17



��in�
this entire Filing.
an "Entity" Search.
��Show�
Docs searched
�and�
every "hit".
the 1st "hit".

Help...�Wildcards:� ? (any letter),� * (many).� Logic:� for Docs:� &�(and),� |�(or);� for Text:� |�(anywhere),� "(&)"�(near).� � ↓Bottom
�
T-->  As Of                Filer                Filing    For�On�As Docs:Size              Issuer               Agent

 9/07/07  Accipiter Life Sciences Fund LP   4          %Own.,Oth.  1:20K  Orchid Cellmark Inc               Olshan Frome Wolosky LLP
          Accipiter Life Sciences Fund Offshore Ltd
          Hoffman Gabe
          Accipiter Capital Management, LLC
          Accipiter Life Sciences Fund II Offshore Ltd
          Accipiter Life Sciences Fund II QP LP
          Accipiter Life Sciences Fund II LP
          Candens Capital LLCF-->Statement of Change in Beneficial Ownership of Securities � � � Form 4Filing Table of Contents
Document/Exhibit                   Description                      Pages   Size 

 1: 4           Statement of Change in Beneficial Ownership of      HTML     17K 
                          Securities -- acc22.xml/2.2                            

D-->P-->

This document is an XML File that may be rendered in various formats:Form 4 �–� Plain Text �–� EDGAR System �–� SEC Website �–� XML Listing �–� <?xml?> File��





FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934or Section 30(h) of the Investment Company Act of 1940


OMB APPROVAL




OMB Number:
3235-0287


Estimated average burden


hours per response:
0.5











X



Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See

Instruction 1(b).




1. Name and Address of Reporting Person*

ACCIPITER CAPITAL MANAGEMENT, LLC





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)



2. Issuer Name and Ticker or Trading Symbol
ORCHID CELLMARK INC
[ ORCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)


﻿
Director
X
10% Owner



﻿
Officer (give title below)

﻿
Other (specify below)



﻿





3. Date of Earliest Transaction
(Month/Day/Year) 9/5/07


4. If Amendment, Date of Original Filed
(Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)



﻿
Form filed by One Reporting Person


X
Form filed by More than One Reporting Person








Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned


1. Title of Security (Instr.
3)

2. Transaction Date
(Month/Day/Year)
2A. Deemed Execution Date, if any
(Month/Day/Year)
3. Transaction Code (Instr.
8)

4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)

5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)

7. Nature of Indirect Beneficial Ownership (Instr.
4)



Code
V
Amount
(A) or (D)
Price




Common Stock, $0.001 Par Value
 9/5/07
﻿
S

﻿
470,248
D
$5.55
513,207
I
By ALSF (Offshore), Ltd. (1)


Common Stock, $0.001 Par Value
 9/5/07
﻿
S

﻿
479,730
D
$5.55
639,881
I
By ALSF II (Offshore), Ltd. (2)


Common Stock, $0.001 Par Value
 9/5/07
﻿
S

﻿
249,023
D
$5.55
368,971
I
By ALSF II (QP), LP (3)


Common Stock, $0.001 Par Value
 9/5/07
﻿
S

﻿
291,247
D
$5.55
323,053
I
By ALSF II, LP (4)


Common Stock, $0.001 Par Value
 9/5/07
﻿
S

﻿
509,752
D
$5.55
512,295
I
By ALSF, LP (5)






Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned(e.g., puts, calls, warrants, options, convertible securities)


1. Title of Derivative Security (Instr.
3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date
(Month/Day/Year)
3A. Deemed Execution Date, if any
(Month/Day/Year)
4. Transaction Code (Instr.
8)

5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)

8. Price of Derivative Security (Instr.
5)

9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)

11. Nature of Indirect Beneficial Ownership (Instr.
4)



Code
V
(A)
(D)
Date Exercisable
Expiration Date
Title
Amount or Number of Shares





1. Name and Address of Reporting Person*

ACCIPITER CAPITAL MANAGEMENT, LLC





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)





1. Name and Address of Reporting Person*

Candens Capital LLC





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)





1. Name and Address of Reporting Person*

HOFFMAN GABE





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)





1. Name and Address of Reporting Person*

ACCIPITER LIFE SCIENCES FUND LP





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)





1. Name and Address of Reporting Person*

ACCIPITER LIFE SCIENCES FUND II L P





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)





1. Name and Address of Reporting Person*

ACCIPITER LIFE SCIENCES FUND OFFSHORE LTD





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)





1. Name and Address of Reporting Person*

Accipiter Life Sciences Fund II Offshore Ltd





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)





1. Name and Address of Reporting Person*

ACCIPITER LIFE SCIENCES FUND II QP L P





(Last)
(First)
(Middle)




399 PARK AVENUE


38TH FLOOR


(Street)

NEW YORK
NY
10022





(City)
(State)
(Zip)







Explanation of Responses:


(1)� Held by Accipiter Life Sciences Fund (Offshore), Ltd. Accipiter Capital Management, LLC, the investment manager of Accipiter Life Sciences Fund (Offshore), Ltd. and Gabe Hoffman, the managing member of Accipiter Capital Management, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.


(2)� Held by Accipiter Life Sciences Fund II (Offshore), Ltd. Accipiter Capital Management, LLC, the investment manager of Accipiter Life Sciences Fund II (Offshore), Ltd. and Gabe Hoffman, the managing member of Accipiter Capital Management, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.


(3)� Held by Accipiter Life Sciences Fund II (QP), LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund II (QP), LP and Gabe Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.


(4)� Held by Accipiter Life Sciences Fund II, LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund II, LP and Gabe Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.


(5)� Held by Accipiter Life Sciences Fund, LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund, LP and Gabe Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.




﻿
By: Accipiter Capital Management; By: /s/ Gabe Hoffman, Managing Member
 9/7/07


﻿
By: Candens Capital, LLC; By: /s/ Gabe Hoffman, Managing Member
 9/7/07


﻿
By: /s/ Gabe Hoffman
 9/7/07


﻿
By: Accipiter Life Sciences Fund, LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member
 9/7/07


﻿
By: Accipiter Life Sciences Fund II, LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member
 9/7/07


﻿
By: Accipiter Life Sciences Fund (Offshore), Ltd.; By: Accipiter Capital Management, LLC, its Investment Manager; By: /s/ Gabe Hoffman, Managing Member
 9/7/07


﻿
By: Accipiter Life Sciences Fund II (Offshore), Ltd.; By: Accipiter Capital Management, LLC, its Investment Manager; By: /s/ Gabe Hoffman, Managing Member
 9/7/07


﻿
By: Accipiter Life Sciences Fund II (QP), LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member
 9/7/07



﻿
** Signature of Reporting Person
Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.


* If the form is filed by more than one reporting person,
see

Instruction
4

(b)(v).


** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see

Instruction 6 for procedure.


﻿




________Transaction Code:
� � S: �Open market or private sale of non-derivative or derivative security.
↑TopFiling Submission 0000921895-07-002096 � – � Alternative Formats (Word / Rich Text, HTML, Plain Text, et�al.)
Copyright � 2017 Fran Finnegan & Company.� All Rights Reserved.About – Privacy – Redactions – Help —
Sat, 22 Jul 02:15:57.0 GMT�










Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft














accipiter fund - Money A2Z - Web Results










AOL Search
Skip over navigation


















Search the Web



























Web





Images


Images










Free Online Fundraising - Raise Money Online for Free Today.



Ad
 ·
youcaring.com/​FreeFundraising



Raise Money Online for Free Today. Easy to Use. Start Fundraising Now!





How it Works



Testimonials




Why it's Free



Start Crowdfunding





Fundbox™ Official Site - Get Paid Instantly With Fundbox.



Ad
 ·
Fundbox.com/​Sign-Up



Get Paid Instantly With Fundbox. Join with Your Invoicing Software!





How It Works



Sign Up




Our Pricing



Learn More about Fundbox™





Top 10 Mutual Funds - Find Top 10 Mutual Funds | searchall.com



Ad
 ·
www.searchall.com/​Mutual+Funds



Search for Top 10 Mutual Funds with 100's of Results at SearchAll.com!





Best Mutual Funds



Compare Mutual Funds



Top 5 Mutual Funds



Top 10 Mutual Funds




Web Results

Hedge Fund - Accipiter Capital Management - Insider Monkey

www.insidermonkey.com/hedge-fund/accipiter+capital+management/166


Accipiter Capital Management is a New York-based healthcare specialist hedge fund that was founded by Gabe Hoffman in 2002. Prior to launching Accipiter, Hoffman ...


Accipiter Fund, LLC in Houston, TX | Company Info & Reviews

https://www.bizapedia.com/tx/accipiter-fund-llc.html


Discover Company Info on Accipiter Fund, LLC in Houston, TX, such as Contacts, Addresses, Reviews, and Registered Agent.


ACCIPITER LIFE SCIENCES FUND v. HELFER | FindLaw

caselaw.findlaw.com/de-court-of-chancery/1053654.html


Case opinion for DE Court of Chancery ACCIPITER LIFE SCIENCES FUND v. HELFER. Read the Court's full decision on FindLaw.


Accipiter Capital Management - HedgeFundJobList

https://hedgefundjoblist.com/accipiter-capital-management


Accipiter Capital Management is a hedge fund management company based in New York, NY and has approximately $316.7 million in assets under management. View email, AUM...


Accipiter Capital Management - Fund Info - hedgelists.com

https://hedgelists.com/blog/hedge-fund-manager-profiles/accipiter...


Accipiter Capital Management is a hedge fund based in New York, NY. Accipiter Capital Management was founded in 2002 and has approximately $343.9 million in


Accipiter Life Sciences Fund (Offshore), Ltd. - graypools

https://www.graypools.com/hedge-fund/805-9355451095


View current and historical demographic and financial information for Accipiter Life Sciences Fund (Offshore), Ltd. and other Hedge Funds.


Accipiter Capital Management Llc – Octafinance

www.octafinance.com/hedge-funds/ACCIPITER-CAPITAL-MANAGEMENT-LLC


Accipiter Capital Management Llc is a Florida-based hedge fund that was founded by Gabe Hoffman. It had more than $316.20 million assets under management in June, 2014.


ACCIPITER CAPITAL MANAGEMENT, LLC Top Holdings

https://whalewisdom.com/filer/accipiter-capital-management-llc


Accipiter Capital Management is based out of Palm Beach Gardens. Accipiter Capital Management is a hedge fund with 1-10 clients and discretionary assets under ...


Accipiter - Mutual Fund Observer Discussions

https://mutualfundobserver.com/discuss/profile/accipiter


Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy ...


The Value Gene: An Interview with Paul Isaac - Barron's

www.barrons.com/articles/SB50001424053111903431804577510631168965436


Paul Isaac's father helped Mutual Shares founder Max Heine find his ... Heine went on to run the legendary Mutual Shares Fund, and Irving Isaac sat on its board for ...










Free Online Fundraising - Raise Money Online for Free Today.



Ad
 ·
youcaring.com/​FreeFundraising



Raise Money Online for Free Today. Easy to Use. Start Fundraising Now!





How it Works



Testimonials




Why it's Free



Start Crowdfunding





Fundbox™ Official Site - Get Paid Instantly With Fundbox.



Ad
 ·
Fundbox.com/​Sign-Up



Get Paid Instantly With Fundbox. Join with Your Invoicing Software!





How It Works



Sign Up




Our Pricing



Learn More about Fundbox™





Top 10 Mutual Funds - Find Top 10 Mutual Funds | searchall.com



Ad
 ·
www.searchall.com/​Mutual+Funds



Search for Top 10 Mutual Funds with 100's of Results at SearchAll.com!





Best Mutual Funds



Compare Mutual Funds



Top 5 Mutual Funds



Top 10 Mutual Funds



12345Next






Answers







Buteo



America (Buteo is the Latin name of the common buzzard). As both terms are ambiguous, buteo is sometimes used instead, for example, by the Peregrine...

more






Falconry



falcon; an austringer (German origin) flies a hawk (Accipiter and some buteos and similar) or an eagle (Aquila or similar). In modern falconry, the...

more






Sharp-shinned hawk



The sharp-shinned hawk (Accipiter striatus) is a small hawk, with males being the smallest hawks in the United States and Canada, but with the species...

more




















Search the Web

















© AOL Inc. All Rights Reserved.Privacy
 | Terms of Use
 | Preferences
 | Contact Us
 | Powered by Bing™

Wow.com - Part of the AOL Search Network















Life Science : Shimadzu Scientific Instruments 








































Gas Chromatography
Liquid Chromatography
Gas Chromatograph-Mass Spectrometry
Liquid Chromatograph-Mass Spectrometry
CL Series Medical Devices
Data Management & Software
Molecular Spectroscopy
Elemental Analysis
Life Science Lab Instruments
Total Organic Carbon Analysis
Thermal Analysis
Universal Testing
Hardness/Viscosity Testing
Particle Size Analysis
High-Speed Video Camera
Balances
X-ray Instruments




Cannabis Testing Solutions
Ceramics, Metals, Mining
Clinical Research, Forensics
Electronics, Electronic
Environmental
Food, Beverages
Life Science
Automotive Materials Testing
Energy, Chemical
Pharmaceutical
Plastics, Polymers and Rubber





Advanced Training












HOME 
>  PRODUCTS 
>   Life Science




Life Science

   Shimadzu's Life Science Lab Instruments are focused on developing new tools to help accelerate life science research by integrating novel chemistry with innovative technology to achieve a unique position as a true provider of solutions for life scientists.
   

   Shimadzu brings together technologies and tools that help you find out more about your biological sample. Whether it is a gel based experiment for understanding protein expression, characterizing differences in metabolism in patient studies, imaging tissue with mass spectrometry, Shimadzu can help you discover more about the biology of disease.
   

  Courtesy of GenomeWeb: Learn about Shimadzu’s portfolio of potential clinical proteomics tools (PDF)
   




Life Science UV-Vis-NIR Spectroscopy





BioSpec-nano




Protein Sequencing





Protein Sequencer




MALDI-TOF Mass Spectrometry





MALDI-7090TM
AXIMA Assurance
AXIMA Confidence
AXIMA Performance
AXIMA Resonance
MegaTOF™ Megadalton MALDI
Glycan Analyzer
Microorganism Identification
Nano Spotter




Integrated Sample Preparation for LCMS





CLAM-2000




Automated Protein Separation





Perfinity Workstation
Perfinity iDP




Dried Plasma Spots





Noviplex Cards




Imaging





LABNIRS
LIGHTNIRS




Cannabis Testing Solutions





Learn More




Informatics





i3D Enterprise Informatics Service










Quotation/Additional Information

Technical Inquiry
Other Inquiry
Product Training
Order Supplies
Join our E-news








May 2017
Shimadzu’s New Nexis GC-2030 Gas Chromatograph Offers a Modern Approach to a Classic Chromatographic Technique


March 2017
Shimadzu’s New Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoid Content


February 2017
Shimadzu and MIDI, Inc. Partner to Bring Automated Chromatographic Data Analysis Solutions to Laboratories of All Sizes


December 2016
Shimadzu’s New LC-MS/MS Offers Exceptional Performance in a Robust, Cost-Effective Design


October 2016
Shimadzu’s New Triple Quadrupole GCMS Achieves World’s Highest Sensitivity Down to Femtogram Level
















PRIVACY POLICY


TERMS OF USE


EMPLOYMENT


SITE MAP




Copyright (C) Shimadzu Scientific Instruments. All Rights Reserved












Product Gateway: Shimadzu Scientific Instruments 
























































Gas Chromatography
Liquid Chromatography
Gas Chromatograph-Mass Spectrometry
Liquid Chromatograph-Mass Spectrometry
CL Series Medical Devices
Data Management & Software
Molecular Spectroscopy
Elemental Analysis
Life Science Lab Instruments
Total Organic Carbon Analysis
Thermal Analysis
Universal Testing
Hardness/Viscosity Testing
Particle Size Analysis
High-Speed Video Camera
Balances
X-ray Instruments




Cannabis Testing Solutions
Ceramics, Metals, Mining
Clinical Research, Forensics
Electronics, Electronic
Environmental
Food, Beverages
Life Science
Automotive Materials Testing
Energy, Chemical
Pharmaceutical
Plastics, Polymers and Rubber





Advanced Training











HOME 
>  PRODUCTS




PRODUCTS



Gas Chromatography





GC-2030
Tracera
GC-2010 Plus
GC-2014
GC-8A




Liquid Chromatography





Nexera X2
Crude2Pure
Nexera SR
i-Series
i-Series Analyzers
Nexera UC
Nexera Quaternary
Nexera MP
Prominence
Prominence UFLC
Prominence UFLCXR




Gas Chromatography Mass Spectrometry





GCMS-TQ8050
GCMS-TQ8040
GCMS-QP2020
GCMS-QP2010 SE




Liquid Chromatograph-Mass Spectrometry





LCMS-8060
LCMS-8050
LCMS-8045
LCMS-8040
LCMS-2020
LCMS-IT-TOF
LCMS Software




CL Series Medical Devices





Learn more




Data Management & Software





LabSolutions
LabSolutions CS
LabSolutions DB
LabSolutions LCGC
CLASS-Agent
LC Driver for Waters Empower™
GC Driver for Waters Empower™ Software
C-R8A
Empower™ 2 Software




Molecular Spectroscopy





UV-Vis-NIR Spectroscopy
FTIR Spectroscopy
Fluorescence Spectroscopy




Elemental Analysis





Atomic Absorption Spectroscopy
Inductively Coupled Plasma Emission Spectroscopy
Energy Dispersive X-ray Fluorescence Spectroscopy
Wavelength Dispersive X-ray Fluorescence Spectroscopy
X-ray Diffraction




Life Science Lab Instruments





Life Science UV-Vis-NIR Spectroscopy
Automated Protein Separation
Protein Sequencing, Peptide Synthesis
Nanotrap Biomarker Discovery Platform
MALDI-TOF Mass Spectrometry
Informatics
Electrophoresis, Chemical Inkjet Printer




Total Organic Carbon Analysis





TOC-L
TOC-Vw Series
Online TOC-Vsh
TOC-4200
TNPC-4110/TNPC-4110C




Universal Testing





Electromechanical Static Test Frames
Hydraulic Static Test Frames
Universal Testing Frame Software- Trapezium X




Thermal Analysis





DSC-60 Plus
DSC-60 Plus with Auto-Cooling
DTG-60/DTG-60A
TMA-60/60H
TGA-50/50H And TGA-51/51H
DTA-50
TA-60WS




Hardness Testing / Viscosity & Flow Testing





DUH-211/DUH-211S
MCT Series
HMV-G Series
Flowtester Capillary Rheometers
Mooney Viscometer




Particle Size Analysis





IG-1000 Plus
SALD-201V
SALD-2300
SALD-301V
SALD-3101
SALD-7101
SALD-7500nano
LATS-1
WingSALD




High-Speed Video Camera





HyperVision HPV-X2
HyperVision HPV-2




Balances





AUW-D Series
AUW Series
AUX Series
AUY Series
ATX/ATY series
UW Series
UX Series
TW/TWC Series
TX/TXB/TXC Series
ELB Series
BW-K/BX-K Series
Animal Balances
SMK Specific Gravity Measurement kit
MOC63u
MOC-120H










Quotation/Additional Information

Technical Inquiry
Other Inquiry
Product Training
Order Supplies
Join our E-news







May 2017
Shimadzu’s New Nexis GC-2030 Gas Chromatograph Offers a Modern Approach to a Classic Chromatographic Technique


March 2017
Shimadzu’s New Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoid Content


February 2017
Shimadzu and MIDI, Inc. Partner to Bring Automated Chromatographic Data Analysis Solutions to Laboratories of All Sizes


December 2016
Shimadzu’s New LC-MS/MS Offers Exceptional Performance in a Robust, Cost-Effective Design


October 2016
Shimadzu’s New Triple Quadrupole GCMS Achieves World’s Highest Sensitivity Down to Femtogram Level
















PRIVACY POLICY


TERMS OF USE


EMPLOYMENT


SITE MAP




Copyright (C) Shimadzu Scientific Instruments. All Rights Reserved

















Office Locations : Shimadzu Scientific Instruments 







































Gas Chromatography
Liquid Chromatography
Gas Chromatograph-Mass Spectrometry
Liquid Chromatograph-Mass Spectrometry
CL Series Medical Devices
Data Management & Software
Molecular Spectroscopy
Elemental Analysis
Life Science Lab Instruments
Total Organic Carbon Analysis
Thermal Analysis
Universal Testing
Hardness/Viscosity Testing
Particle Size Analysis
High-Speed Video Camera
Balances
X-ray Instruments




Cannabis Testing Solutions
Ceramics, Metals, Mining
Clinical Research, Forensics
Electronics, Electronic
Environmental
Food, Beverages
Life Science
Automotive Materials Testing
Energy, Chemical
Pharmaceutical
Plastics, Polymers and Rubber













HOME 
>  ABOUT Shimadzu Scientific
>  Office Locations	




Office Locations




							If you are searching for a Shimadzu location outside of North and South America, please click here.
                   		 








Shimadzu Distributor Locations
For Physical Measurement Distributors, click here
For North American Balance Distributors, click here
For Canada, click here
For Mexico, Centro America, the Caribbean and parts of South America  click here




Shimadzu North America / Shimadzu Scientific Instruments, Inc. -- USA Headquarters


         
                           7102 Riverwood DriveColumbia, MD 21046	 USA
                            Phone: 410-381-1227/ 800-477-1227
                            Fax: 410-381-1222
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - Mid-Atlantic)


         
                           7102 Riverwood DriveColumbia, MD 21046	 USA
                            Phone: 410-381-6996/800-388-6996
                            Fax: 410-290-9140
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - New England)


         
                           62 Forest Street Suite 110 Marlborough, MA  01752	 USA
                            Phone: 508-573-3440/800-396-4943
                            Fax: 800-590-0797
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - New Jersey)


         
                           19 Schoolhouse RoadSuite 107Somerset NJ 08873	 USA
                            Phone: 732-893-5400/800-439-8555
                            Fax: 732-271-2585
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - California)


         
                           7060 Koll Center ParkwaySuite 328Pleasanton, CA 94566	 USA
                            Phone: 925-417-2090/800-482-0253
                            Fax: 925-462-7348
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - North Carolina)


         
                           4022 Stirrup Creek DriveSuite 312Durham, NC 27703	 USA
                            Phone: 800-951-9167/919-425-1010
                            Fax: 919-544-3497
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - Chicago)


         
                           2055 Army Trail Road - Suite 106Addison, IL  60101	 USA
                            Phone: 630-916-6286/800-792-1992
                            Fax: 630-916-7160
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - Kansas)


         
                           8052 Reeder StreetLenexa, KS 66214	 USA
                            Phone: 913-888-9449/877-698-7923
                            Fax: 913-888-8388
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - Houston)


         
                           9940 W. Sam Houston Pkwy. South, Suite 300Houston, TX 77099	 USA
                            Phone: 713-467-1151 or 800-739-1942
                            Fax: 713-467-1153
                            Products:  All Shimadzu Scientific Instruments 
                        
                            


Shimadzu North America (Regional Office - Southern California) 


         
                           1930 Palomar Point Way Suite 107Carlsbad, CA 92008	 USA
                            Phone: 866-862-1677 /760-710-2400
                            Fax: 760-931-9854
                            Products:  All Shimadzu Scientific Instruments
                        
                            


Shimadzu U.S.A. Manufacturing, Inc 


         
                           1900 Southeast 4th AvenueCanby, OR 97013	 USA
                            Phone: 503-263-2133
                            Fax: 503-263-1763
                            Products:  Manufactures Shimadzu HPLC/GCMS Products
                        
                            info@ShimadzuSUM.com


Shimadzu Medical Systems


         
                           20101 S Vermont AveTorrance, CA 90502	 USA
                            Phone: 310-217-8855
                            Fax: 310-217-0661
                            Products:  Medical Systems/Equipment
                        
                            info@shimadzumed.com


Shimadzu Precision Instruments 


         
                           3645 N. Lakewood Blvd. 
Long Beach, CA 90808	 USA
                            Phone: 562-420-6226
                            Fax: 562-420-6446
                            Products:  Aircraft Equipment
                        
                            info@spi-inc.com


Kratos Analytical 


         
                           100 Red Schoolhouse Road, Bldg AChestnut Ridge, NY 10977	 USA
                            Phone: 914-426-6700
                            Fax: 914-426-6192
                            Products:  Surface, TOFMaldi, X-Ray Products
                        
                            dsurman@kratos.com










 Corporate Information
 Employment Section 
 Current Promotions
 Corporate Shimadzu Magazine 
 Tradeshows and Conferences 
 Office Directions 
 Office Locations 
 Other Offices 
 Sales Rep Locator 
 Shimadzu In the Community
 Sign-up for our E-news 
 ISO Certified Facilities 
















PRIVACY POLICY


TERMS OF USE


EMPLOYMENT


SITE MAP




Copyright (C) Shimadzu Scientific Instruments. All Rights Reserved












Support: Shimadzu Scientific Instruments 























































Gas Chromatography
Liquid Chromatography
Gas Chromatograph-Mass Spectrometry
Liquid Chromatograph-Mass Spectrometry
CL Series Medical Devices
Data Management & Software
Molecular Spectroscopy
Elemental Analysis
Life Science Lab Instruments
Total Organic Carbon Analysis
Thermal Analysis
Universal Testing
Hardness/Viscosity Testing
Particle Size Analysis
High-Speed Video Camera
Balances
X-ray Instruments




Cannabis Testing Solutions
Ceramics, Metals, Mining
Clinical Research, Forensics
Electronics, Electronic
Environmental
Food, Beverages
Life Science
Automotive Materials Testing
Energy, Chemical
Pharmaceutical
Plastics, Polymers and Rubber














HOME 
>  SUPPORT




SUPPORT



Inquiry

Product Inquiry (Do you have a product related question? Need a quote on a product?)  
Technical Inquiry (Do you need technical assistance with your product?)  
Customer Service Inquiry  (Need help determining if a part is in stock?) 
                           Chat with customer service (click image to activate chat once it loads)



Our customer service hours are 8:30AM TO 5:00 PM EST.



Need MSDS/SDS (Material Safety Data Sheets)?


Order Supplies For Your Instruments (external link)   Consumables, accessories, manuals and more. 

Consumable Guides


Shimadzu Global Contact (external link)

Please feel free to contact us, if you have any questions about our products, service or support.


Sales Representative Search - US only
To locate the Shimadzu representative(s) closest to you, by zip code


Training
Are you looking for the training section of our website? Click here to learn more.


Virtual Advisor
Shimadzu has launched its interactive "Virtual Advisor" websites to further enhance customer service.

i-Series Virtual Advisor
Prominence Virtual Advisor
Nexera Virtual Advisor
TOC-V Virtual Advisor
TOC-L Virtual Advisor



Tutorials
Fundamentals of GC/MS – Click here to learn more.


Mailing Address
Shimadzu Scientific Instruments
                    7102 Riverwood Drive
                    Columbia, MD 21046
                    U.S.A.
                    Phone Number: 1-800-477-1227
                    Fax Number: 410-381-1222 








Quotation/Additional Information

Technical Inquiry
Other Inquiry
Product Training
Order Supplies
Join our E-news















PRIVACY POLICY


TERMS OF USE


EMPLOYMENT


SITE MAP




Copyright (C) Shimadzu Scientific Instruments. All Rights Reserved















News/Events: Shimadzu Scientific Instruments 


















































Gas Chromatography
Liquid Chromatography
Gas Chromatograph-Mass Spectrometry
Liquid Chromatograph-Mass Spectrometry
CL Series Medical Devices
Data Management & Software
Molecular Spectroscopy
Elemental Analysis
Life Science Lab Instruments
Total Organic Carbon Analysis
Thermal Analysis
Universal Testing
Hardness/Viscosity Testing
Particle Size Analysis
High-Speed Video Camera
Balances
X-ray Instruments




Cannabis Testing Solutions
Ceramics, Metals, Mining
Clinical Research, Forensics
Electronics, Electronic
Environmental
Food, Beverages
Life Science
Automotive Materials Testing
Energy, Chemical
Pharmaceutical
Plastics, Polymers and Rubber





Advanced Training











HOME 
>  NEWS/EVENTS




NEWS/EVENTS






May 10 2017
Shimadzu’s New Nexis GC-2030 Gas Chromatograph Offers a Modern Approach to a Classic Chromatographic Technique



March 29 2017
Shimadzu’s New Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoid Content



February 27 2017
Shimadzu and MIDI, Inc. Partner to Bring Automated Chromatographic Data Analysis Solutions to Laboratories of All Sizes



December 5 2016
Shimadzu’s New LC-MS/MS Offers Exceptional Performance in a Robust, Cost-Effective Design



October 11 2016
Shimadzu’s New Triple Quadrupole GCMS Achieves World’s Highest Sensitivity Down to Femtogram Level



September 6 2016
Shimadzu’s New Integrated HPLC BioEthanol Analyzer Offers Round-the-Clock QC Testing at Bioethanol Production Plants


More News...








 July 23-26, 2017
North American Pesticide Residue Workshop (FPRW)



 August 1-3, 2017
Denver X-Ray Conference



 August 1-3, 2017
AACC-Mass Spectrometry in the Clinical Lab: Best Practices and Current Applications



 August 7-9, 2017
National Environmental Monitoring Conference (NEMC)



 August 20-22, 2017
National American Chemical Society - Fall



 August 28-30, 2017
Cannabis Science Conference


More Events...













 NEWS





2017
2016
2015
2014
2013





 EVENTS










Quotation/Additional Information

Technical Inquiry
Other Inquiry
Product Training
Order Supplies
Join our E-news














PRIVACY POLICY


TERMS OF USE


EMPLOYMENT


SITE MAP




Copyright (C) Shimadzu Scientific Instruments. All Rights Reserved










